Genelux (NASDAQ: GNLX) posts updated February 2026 corporate deck

Rhea-AI Filing Summary

Genelux Corporation filed a current report outlining an update to its corporate presentation with new business and strategic information. The refreshed presentation, dated February 2026, may be used by management in future meetings and is available in the Investors section of the company’s website.

The presentation is furnished as Exhibit 99.1 under a Regulation FD disclosure and is not deemed filed for liability purposes under the Exchange Act or incorporated into other securities filings unless specifically referenced.

false 0001231457 0001231457 2026-02-02 2026-02-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 2, 2026

Genelux Corporation

(Exact name of registrant as specified in its charter)

Delaware		001-41599		77-0583529
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)
2625 Townsgate Road, Suite 230 Westlake Village, California				91361
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (805) 267-9889

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		GNLX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On February 2, 2026, Genelux Corporation (the “Company”) updated its corporate presentation (the “Corporate Presentation”) with certain business and strategic updates. Information from the Corporate Presentation may be used by the management of the Company in future meetings regarding the Company and will also be available in the “Investors” section of the Company’s website at investors.genelux.com. A copy of the presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The Company’s website and any information contained in the Company’s website are not incorporated into this Current Report on Form 8-K. For important information about forward-looking statements in the Corporate Presentation, see the slide titled “Disclaimer” in Exhibit 99.1 attached hereto.

The information contained or incorporated in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”) except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Corporate Presentation, dated February 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Genelux Corporation
Date: February 2, 2026	By:	/s/ Thomas Zindrick, J.D.
		Thomas Zindrick, J.D. President and Chief Executive Officer

FAQ

What did Genelux (GNLX) disclose in this 8-K filing?

Genelux disclosed an update to its corporate presentation. The filing states that the February 2026 presentation contains business and strategic updates and may be used in future meetings, and it is furnished as Exhibit 99.1 under a Regulation FD disclosure.

Where can investors access Genelux (GNLX) updated corporate presentation?

The updated corporate presentation is available on Genelux’s website. The filing notes it will be posted in the “Investors” section at investors.genelux.com, and the same presentation is also attached to the report as Exhibit 99.1 for easy investor access.

How is the Genelux (GNLX) corporate presentation treated under SEC rules?

The corporate presentation is treated as furnished, not filed. The company specifies that Exhibit 99.1 is furnished under Item 7.01 of the Exchange Act and is not subject to Section 18 liabilities or incorporated into other filings unless specifically referenced.

What is included as exhibits in this Genelux (GNLX) 8-K?

The 8-K includes two primary exhibits. Exhibit 99.1 is the updated Corporate Presentation dated February 2026, and Exhibit 104 is the cover page interactive data file embedded within the Inline XBRL document, reflecting the technical filing requirements.

Who signed the February 2, 2026 Genelux (GNLX) 8-K?

The 8-K was signed on behalf of Genelux by its President and CEO. The report shows that Thomas Zindrick, J.D., President and Chief Executive Officer, executed the filing for the company on February 2, 2026, under the Exchange Act requirements.